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Counterpoint: Postprandial Glucose Levels
Are Not a Clinically Important Treatment
Target
T
he recently published randomized
controlled Nateglinide And Valsar-
tan in Impaired Glucose Tolerance
Outcomes Research (NAVIGATOR)
studyevaluatedtheeffectofnateglinidein
people with impaired glucose tolerance
(IGT) who also had cardiovascular dis-
ease (CVD) or CVD risk factors (1). After
a median of ﬁve years, there was no effect
oneitherincidentdiabetesorCVD.Inﬁve
studies (2–6) in which the development
of diabetes in subjects with IGT was de-
layed by lifestyle intervention or drugs,
the beneﬁcial effect was postulated to be
mainly due to decreasing insulin resis-
tance with resulting less demands on
-cell insulin secretion. On the other
hand, subjects with IGT in an older small
study treated with tolbutamide (a ﬁrst-
generation sulfonylurea agent) (7) or in
the more recent Study To Prevent Non-
insulin-Dependent Diabetes Mellitus
(STOP-NIDDM)givenacarbose(8),there
was signiﬁcantly less incident diabetes
than in their control groups. (The STOP-
NIDDM study, however, has been se-
verelycriticized[9]).Neithertolbutamide
nor acarbose are thought to primarily af-
fect insulin resistance. It is very possible,
ofcourse,thatallofthesedrugsweresim-
ply masking the development of diabetes
by treating hyperglycemia (10). If so,
nateglinide was unable to accomplish
this.
The rationale for the CVD end point
in the NAVIGATOR study might have
been that glucose levels after a glucose
challenge, extending all the way down
into the midnormal range, are associated
with CVD (11). It is important to point
outthatinmanyarticlespostprandialglu-
cose is used mistakenly to describe glu-
cose levels after the nonphysiologic large
amount of glucose ingested for the oral
glucose tolerance test. In the only study I
could ﬁnd in which CVD events were re-
lated to postprandial glucose concentra-
tions, i.e., after meals, these levels were
more predictive than fasting plasma glu-
cose (FPG) concentrations in a bivariate
analysis (12). In a multivariate analysis,
only the value after lunch remained sig-
niﬁcant. Since nateglinide has a more
profoundeffectonpostprandialglucose
concentrations than on fasting ones in
people with diabetes, it was chosen to
test the hypothesis that lowering post-
prandial glucose levels might have a
beneﬁcial effect on people at risk for
CVD and the development of diabetes.
That it did not might not be too surpris-
ing because day-to-day glucose levels in
people with IGT on weight maintaining
diets (35 kcal/kg) were not increased
(13–15). On the other hand, the per-
haps problematic STOP-NIDDM study
showed that acarbose was associated
with decreased incidents of CVD and
hypertension (16).
However, in contrast with people
with IGT, postprandial glucose concen-
trations are certainly increased in diabetic
patients. There is much speculation that
speciﬁcallytargetingtheselevelsmightbe
beneﬁcial for both the microvascular and
macrovascular complications of diabetes
(17). Brownlee (18) laid out an intricate
theoretical framework of how postpran-
dialhyperglycemiamightcausethewhole
gamut of diabetic complications. This in-
volves increasing glucose concentrations
causing oxidative stress reﬂected in al-
tered mitochondrial function, which
causes inhibition of glyceraldehyde phos-
phate dehydrogenase. This, in turn, leads
to increased activity of four biochemical
pathways associated with the complica-
tions of diabetes, i.e., the polyol, hex-
osamine, protein kinase C, and advanced
glycation end product pathways. Could
thisbethemechanismwherebytherisein
postprandial glucose concentrations
leads to diabetic complications? Let’s ex-
amine the evidence for this intriguing
hypothesis.
In vitro incubations of various tissues
and cell lines with increasing concentra-
tions of glucose lead to products that re-
ﬂect oxidative stress (19). One study (20)
did show that mitochondrial function in
biopsies from the muscle of diabetic sub-
jectswasimpairedwhilethreeotherstud-
ies (21–23) could not conﬁrm this
ﬁnding.
Increasedvariabilityofdailyglycemia
is often taken as a surrogate measure for
higher postprandial glucose excursions
(24).Yetretinopathywasunrelatedtothis
variability, although it remained related
to mean glycemia (25). Urinary excretion
offree8-iso-PGF2ispostulatedtoreﬂect
oxidativestress,anditsexcretionisinhib-
ited by vitamin E, an antioxidant (26).
One study did ﬁnd that glucose variabil-
ity, measured by the mean amplitude of
glycemic excursions, was positively cor-
related with urinary free 8-iso-PGF2
(27), but this could not be conﬁrmed in
twootherstudies(28,29).Rather,urinary
free 8-iso-PGF2 levels were increased in
diabetic patients and lowered by im-
proved diabetic control (26).
Endothelial dysfunction is an early
manifestation of atherosclerosis (30). En-
dothelial function, measured by ﬂow-
mediated dilation, decreased in people
with diabetes after eating in association
with rising postprandial glucose levels
but did not change in healthy subjects
who have much less of a postprandial rise
(31). Artiﬁcially raising glucose concen-
trations with intravenous glucose also de-
creased ﬂow-mediated dilation and
increased oxidative stress, as reﬂected in
increased plasma nitrotyrosine, in both
healthy subjects and type 2 diabetic pa-
tients (32). Both of these responses to in-
travenous glucose were blocked by an
infusionofvitaminC,alsoanantioxidant,
in healthy subjects but not in those with
diabetes (33).
Carotidarteryintima-medialthicken-
ing (CIMT) reﬂects coronary artery dis-
ease (34). In a cross-sectional study,
CIMT correlated with the postprandial
rise in glucose concentrations (35). In a
prospective study, CIMT did not change
in patients treated for three years with vo-
glibose, an -glucosidase inhibitor, com-
pared with a 0.1 mm increase in those
given a placebo with a signiﬁcant differ-
ence between the two groups (36). In an-
other prospective study in drug-naïve
patients, there was a small but signiﬁcant
0.03 mm decrease in CIMT over 1 year in
a large number of patients treated with
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with glyburide (37).
In terms of clinical events, a meta-
analysisevaluatedsevenrandomized,pla-
cebo-controlled acarbose studies carried
outbetween1987and1999.Theprimary
outcomemeasurewasthetimetodevelop
a CVD event. There was a signiﬁcant 2%
reduction over a 2-year period in the per-
cent of type 2 diabetic patients treated
with acarbose who suffered a CVD event
(38). These patients also had signiﬁcant
reductions in A1C and FPG levels as well
as postprandial glucose levels. On the
other hand, documented signiﬁcant low-
ering of postprandial glucose levels in the
recent Hyperglycemia and Its Effect After
Acute Myocardial Infarction on Cardio-
vascular Outcomes in Patients With Type
2 Diabetes Mellitus (HEART2D) study by
premeal lispro insulin in diabetic patients
with a recent acute myocardial infarction
did not decrease the recurrence of a CVD
event compared with basal NPH or
glargine insulin, which signiﬁcantly low-
ered FPG concentrations (39). There was
no difference in A1C levels between the
two groups during this study.
How do these data serve to inﬂuence
our clinical approach to postprandial hy-
perglycemia? The most important deter-
minant of the postprandial glucose
concentration is the preprandial level.
Furthermore, the increment over the pre-
prandial level is similar regardless of the
preprandial value (40–42). Therefore,
postprandial hyperglycemia is best
treatedbyloweringpreprandialglycemia.
Sincerandomizedcontrolledintervention
studies have clearly demonstrated that
keeping A1C levels below 7.0% is beneﬁ-
cial for the microvascular complications
of diabetes (43–45) (although perhaps
not for the macrovascular ones [46–48]),
that should be our primary goal. Once
preprandial glucose targets are attained
and if A1C levels are 7.0%, then and
only then would speciﬁcally targeting
postprandial glycemia be appropriate. If
preprandial glucose values are reached
and A1C levels are 7.0%, current clini-
cal evidence is not strong enough to ex-
posethesepatientstotheincreasedriskof
hypoglycemia by aggressively targeting
postprandial glycemia.
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